<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">The global health emergency resulting from the COVID-19 pandemic is a special concern to rheumatologists and their patients, as most patients seen by rheumatologists have underlying immune dysfunction and are commonly treated with immunosuppressive therapies. Such therapies are often highly effective for rheumatic disease treatment but can increase the risk of serious infections
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>
 </sup>, which has raised concern that these individuals might be more vulnerable to severe COVID-19 than the general population.
</p>
